当前位置:首页 > 报告详情

德勤:2021年中国生物制药创新趋势展望报告(英文版)(80页).pdf

上传人: 云闲 编号:46380 2021-07-23 80页 1.50MB

1、Outlook on biopharmainnovation trends in ChinaJuly 2021Outlook on biopharma innovation trends in China | ContentsContentsPreface1. Innovative breakthroughs in the global biopharma industryBiopharma innovation is accelerating amid digital transformationApplication of AI in the entire medical industri

2、al chain is accelerating technical breakthroughsBiopharma enterprises R&D priorities are shifting to innovation of targets and the development of new-generation therapies2. Innovation trends in Chinas biopharma industryInnovative biologics are increasingly valued by government agencies; R&D and mark

3、et access are acceleratingChina becoming a digital transformation powerhouse for biopharma enterprisesInnovation breakthroughs as AI empowers the entire biopharma industrial chainNew-generation therapy: China a burgeoning market for CGTInnovation and implementation capabilities are shifting from MNC

4、s to local enterprises3. Conditions in Chinas biopharma industryRegulatory policies reform: the main areas and core policiesR&D models: innovative transformation and international cooperationLaunched products types: from universal innovation to leading innovationInvestment and M&A are creating innov

5、ative biopharma portfoliosFrom Importing to China to Exported from China4. Innovative biopharma development in the Yangtze River DeltaPolicy support: National and provincial policies promote regional integrationTalent accumulation: Top industrial talent is being brought in to accelerate scientific i

6、nnovation and reformCapital strength: Substantial capital support is being provided to enable innovative corporate development in the Yangtze River Delta5. Challenges and suggestions for biopharma innovation in ChinaEndnotes 1591215212124273034404145485153565660616770Outlook on biopharma innovation

word格式文档无特别注明外均可编辑修改,预览文件经过压缩,下载原文更清晰!
三个皮匠报告文库所有资源均是客户上传分享,仅供网友学习交流,未经上传用户书面授权,请勿作商用。
本文主要探讨了全球和中国生物制药创新趋势。全球生物制药创新正在加速,数字技术的应用推动了整个产业链的技术突破,生物制药企业的研发重点正在转向目标和新一代疗法的创新。中国生物制药行业也经历了创新热潮,预计到2022年市场规模将超过4万亿元人民币。中国正在成为生物制药企业数字转型的强国,新一代疗法如细胞基因治疗(CGT)在中国市场日益增长。同时,中国生物制药企业正在从跨国公司的创新和实施能力向本地企业转移。中国生物制药行业面临监管政策改革、研发模式创新、产品类型创新、投资和并购等挑战。在长三角地区,政策支持、人才积累和资本实力为生物制药创新提供了有利条件。然而,基础研究和人才吸引仍是该地区面临的主要挑战。
中国生物制药创新趋势如何? 数字技术如何推动全球生物制药创新? 中国生物制药行业面临哪些挑战?
客服
商务合作
小程序
服务号
折叠